Valuation : Celldex Therapeutics, Inc.

Market Cap 311.61Cr 268.14Cr 252.28Cr 230.46Cr 431.12Cr 29TCr 432.29Cr 2.98TCr 1.16TCr 15TCr 1.17TCr 1.14TCr 49TCr P/E 2026 *
-9.51x
P/E 2027 * -9.46x
Enterprise Value 245.37Cr 211.14Cr 198.66Cr 181.47Cr 339.48Cr 23TCr 340.41Cr 2.35TCr 910.92Cr 12TCr 921.4Cr 901.3Cr 38TCr EV / Sales 2026 *
1,234x
EV / Sales 2027 * 208x
Free-Float
99.73%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Celldex Therapeutics, Inc.

Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 67 30/07/2014
Chief Executive Officer 64 01/09/2008
Director of Finance/CFO 55 01/04/2009
Director TitleAgeSince
Director/Board Member 64 01/12/2008
Chairman 80 05/06/2025
Director/Board Member 93 01/03/2008
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 309.17Cr
-2.54%-2.84%-1.90%+14.52% 5.03TCr
-0.40%+1.03%+439.20%+499.20% 4.52TCr
-1.42%+2.30%+45.46%+19.36% 4.47TCr
-1.22%-2.31%+12.40%+71.48% 4.12TCr
+0.53%-1.67%+15.16%+49.88% 3.31TCr
-0.21%+9.14% - - 1.78TCr
-0.35%-1.56%+22.59%+116.19% 1.66TCr
-1.01%+0.50%+15.83%+27.98% 1.48TCr
-1.65%-1.03%+77.75%+37.63% 1.4TCr
Average -0.92%+0.01%+78.31%+104.53% 3.09TCr
Weighted average by Cap. -1.04%-0.46%+94.24%+121.65%

Financials

2026 *2027 *
Net sales 19.88L 17.11L 16.1L 14.7L 27.51L 19Cr 27.58L 1.9Cr 73.81L 9.63Cr 74.65L 73.03L 31Cr 1.19Cr 1.03Cr 96.51L 88.17L 1.65Cr 112.55Cr 1.65Cr 11Cr 4.43Cr 58Cr 4.48Cr 4.38Cr 186.04Cr
Net income -32Cr -27Cr -26Cr -23Cr -44Cr -2.99TCr -44Cr -303.42Cr -117.74Cr -1.54TCr -119.09Cr -116.5Cr -4.95TCr -36Cr -31Cr -29Cr -26Cr -49Cr -3.35TCr -49Cr -339.77Cr -131.85Cr -1.72TCr -133.36Cr -130.45Cr -5.54TCr
Net Debt -66Cr -57Cr -54Cr -49Cr -92Cr -6.25TCr -92Cr -633.64Cr -245.88Cr -3.21TCr -248.71Cr -243.28Cr -10TCr -64Cr -55Cr -52Cr -47Cr -88Cr -6.02TCr -88Cr -609.94Cr -236.69Cr -3.09TCr -239.41Cr -234.19Cr -9.95TCr
Logo Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
39.68USD
Average target price
58.07USD
Spread / Average Target
+46.34%

Quarterly revenue - Rate of surprise